BioCardia, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Peter A. Altman
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 320 Soquel Way Sunnyvale CA United States of America 94085
- IPO Date
- Nov 13, 1996
- CIK
- 0000925741
- Website
- biocardia.com
- Similar Companies
- Business
- BioCardia, Inc. BioCardia, Inc. (NASDAQ:BCDA) is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases with significant unmet needs. The company advances two primary biotherapeutic platforms derived from bone marrow cells: the CardiAMP autologous mononuclear cell therapy system, in Phase III clinical trials for ischemic heart failure with reduced ejection fraction and refractory angina from chronic myocardial ischemia, featuring a point-of-care potency screening assay and proprietary Helix biotherapeutic delivery system; and the CardiALLO allogeneic mesenchymal stem cell therapy platform, in Phase I/II trials for ischemic heart failure and under investigation via PulmALLO for acute respiratory distress syndrome, utilizing Helix or Morph delivery systems. It also offers the FDA 510(k)-cleared Helix intramyocardial delivery system with helical needle for optimal cell retention and the Morph deflectable guide catheter for precise navigational control in interventional cardiology procedures; these delivery technologies support its therapies and hold potential for licensing to third parties. BioCardia, Inc. operates primarily in the United States, targeting patients with severe heart failure and related conditions through clinical trials at multiple sites, with products distributed via networks to healthcare professionals and institutions. Founded effectively in 2016 through a reverse merger acquiring assets from Bioheart, Inc. (established 1999), the company is headquartered in Sunnyvale, California. Recent developments include a March 2024 long-term partnership with StemCardia, Inc. designating BioCardia as the exclusive delivery partner for StemCardia's pluripotent stem cell therapy in heart failure, advancing toward IND filing and Phase I/II trials; an August 2025 exclusive agreement with CART-Tech B.V. to develop and commercialize Heart3D Fusion Imaging for augmented fluoroscopy in cardiac interventions, targeting potential $100 million annual revenue from cloud-based services if adopted as standard care; a $6 million financing in Q3 2025 to support CardiAMP regulatory discussions with FDA and Japan PMDA; and the November 2025 appointment of Farhan Shahab as Vice President of Quality to bolster regulatory submissions and commercialization efforts.
Company News
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript
BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
New Strong Sell Stocks for July 28th
New Strong Sell Stocks for July 14th
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
BioCardia Announces $4.4 Million Financing
Why Is BioCardia Stock Gaining Friday?
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026
BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways